Legend Biotech Corp
LEGN34.530USD
+0.249+0.73%
交易中 （美东）报价延迟15分钟
6.34B总市值
亏损市盈率 TTM
关于 Legend Biotech Corp 公司
传奇生物科技股份有限公司是一家临床阶段的生物制药公司。该公司致力于发现和开发用于肿瘤和其他适应症的细胞疗法。其主要候选产品 ciltacabtagene autoleucel (cilta-cel)，简称 LCAR- B38M，是一种自体嵌合抗原受体 (CAR-T) 细胞疗法，靶向 B 细胞成熟抗原 (BCMA)，这是一种在多种血液系统恶性肿瘤（包括多发性骨髓瘤 (MM)）中高表达的蛋白质。除了 cilta-cel，该公司还拥有一系列针对各种癌症的早期自体 CAR-T 候选产品，包括非霍奇金淋巴瘤、急性淋巴细胞白血病、胃癌、食道癌、胰腺癌、结直肠癌、肝细胞癌、小细胞肺癌和非小细胞肺癌。该公司还致力于开发针对 BCMA 治疗 MM 的同种异体伽马德尔塔 CAR-T 候选产品和同种异体 CAR-NK 候选产品。
公司简介
公司代码LEGN
公司名称Legend Biotech Corp
上市日期Jun 04, 2020
成立日期2015
CEODr. Ying Huang, Ph.D.
员工数量2600
证券类型Depository Receipt
年结日Jun 04
公司地址2101 Cottontail Lane
城市SOMERSET
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编08873
电话17328505598
网址https://investors.legendbiotech.com/
公司代码LEGN
上市日期Jun 04, 2020
成立日期2015
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
United States
579.05M
92.32%
Europe
47.87M
7.63%
China
320.00K
0.05%
业务
地区
暂无数据
股东统计
更新时间: 4月26日 周六
更新时间: 4月26日 周六
持股股东
股东类型
持股股东
股东统计
占比
Fidelity Management & Research Company LLC
6.38%
RA Capital Management, LP
4.09%
T. Rowe Price Associates, Inc.
3.70%
HHLR Advisors, Ltd.
3.26%
Westfield Capital Management Company, L.P.
3.11%
Other
79.46%
持股股东
股东统计
占比
Fidelity Management & Research Company LLC
6.38%
RA Capital Management, LP
4.09%
T. Rowe Price Associates, Inc.
3.70%
HHLR Advisors, Ltd.
3.26%
Westfield Capital Management Company, L.P.
3.11%
Other
79.46%
股东类型
股东统计
占比
Investment Advisor
19.55%
Investment Advisor/Hedge Fund
18.45%
Hedge Fund
13.79%
Research Firm
2.70%
Corporation
1.25%
Venture Capital
0.53%
Bank and Trust
0.30%
Sovereign Wealth Fund
0.09%
Individual Investor
0.08%
Other
43.26%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
539
104.38M
56.84%
-4.11M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
2023Q2
459
88.99M
49.23%
+9.84M
2023Q1
421
72.14M
43.70%
-3.07M
2022Q4
415
67.29M
40.76%
-7.51M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
11.71M
6.38%
-4.86M
-29.35%
Dec 31, 2024
RA Capital Management, LP
7.51M
4.09%
--
--
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.80M
3.7%
-4.36M
-39.04%
Dec 31, 2024
HHLR Advisors, Ltd.
5.98M
3.26%
-651.95K
-9.82%
Dec 31, 2024
Westfield Capital Management Company, L.P.
5.71M
3.11%
+675.19K
+13.40%
Dec 31, 2024
Suvretta Capital Management, LLC
3.50M
1.9%
+3.50M
--
Dec 31, 2024
Invesco Advisers, Inc.
3.29M
1.79%
+1.02M
+45.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.26M
1.77%
-21.07K
-0.64%
Dec 31, 2024
Braidwell LP
2.98M
1.62%
+1.44M
+93.18%
Dec 31, 2024
Citadel Advisors LLC
2.90M
1.58%
+1.59M
+120.64%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Harbor Health Care ETF
7.94%
Matthews Emerging Markets Sustainable Future Active ETF
4.28%
Matthews Emerging Markets Discovery Active ETF
3.82%
Global X Genomics & Biotechnology ETF
3.72%
Tema Oncology ETF
2.77%
KraneShares MSCI All China Health Care Index ETF
1.77%
Virtus LifeSci Biotech Products ETF
1.59%
Range Cancer Immunotherapy ETF
1.2%
iShares Biotechnology ETF
0.4%
WisdomTree China ex-State-Owned Enterprises Fund
0.31%
查看更多
Harbor Health Care ETF
占比7.94%
Matthews Emerging Markets Sustainable Future Active ETF
占比4.28%
Matthews Emerging Markets Discovery Active ETF
占比3.82%
Global X Genomics & Biotechnology ETF
占比3.72%
Tema Oncology ETF
占比2.77%
KraneShares MSCI All China Health Care Index ETF
占比1.77%
Virtus LifeSci Biotech Products ETF
占比1.59%
Range Cancer Immunotherapy ETF
占比1.2%
iShares Biotechnology ETF
占比0.4%
WisdomTree China ex-State-Owned Enterprises Fund
占比0.31%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据